This clinical trial is focused on studying the response to a vaccine called Pneumovax 23, which is used to protect against infections caused by a type of bacteria known as pneumococcus. Pneumococcus can lead to serious illnesses such as pneumonia, meningitis, and bloodstream infections. The vaccine contains 23 different types of pneumococcal polysaccharides, which are substances that help the body recognize and fight off these bacteria.
The purpose of the study is to observe the long-term outcomes in patients who have received a kidney transplant and are considered to be at low risk for immune system complications. These patients are being treated with a medication called tacrolimus, either alone or in combination with another drug called mycophenolate mofetil. The study will compare the survival of the transplanted kidney and the overall health of the patients under these different treatment plans.
Participants in the study will receive the Pneumovax 23 vaccine and their response to the vaccine will be measured at various points over several years. This includes checking the levels of antibodies, which are proteins made by the immune system to fight infections, at 3 and 5 years after the initial vaccination, and again after a booster shot given 5 years later. The study will also monitor other health aspects such as kidney function, patient survival, and any episodes of rejection or infections. This research aims to provide valuable information on how well the vaccine works in kidney transplant patients and how it might affect their long-term health.
The Netherlands 
